These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

96 related items for PubMed ID: 2315511

  • 21. Pharmacokinetic analysis of topotecan after intra-vitreal injection. Implications for retinoblastoma treatment.
    Buitrago E, Höcht C, Chantada G, Fandiño A, Navo E, Abramson DH, Schaiquevich P, Bramuglia GF.
    Exp Eye Res; 2010 Jul; 91(1):9-14. PubMed ID: 20307538
    [Abstract] [Full Text] [Related]

  • 22. Prostaglandin E2 Levels of Aqueous and Vitreous Humor in Ketorolac 0.4% and Nepafenac 0.1% Administered Healthy Rabbits.
    Acar U, Acar DE, Tanriverdi C, Acar M, Ozdemir O, Erikci A, Ornek F.
    Ocul Immunol Inflamm; 2017 Jun; 25(3):323-327. PubMed ID: 26765265
    [Abstract] [Full Text] [Related]

  • 23. Transpupillary irradiation of the rabbit retina with the cw-Nd:YAG laser. I. Acute morphologic effects produced using two different pulse forms.
    van der Zypen E, Fankhauser F, Kwasniewska S, England C.
    Invest Ophthalmol Vis Sci; 1990 Jan; 31(1):29-40. PubMed ID: 2298540
    [Abstract] [Full Text] [Related]

  • 24. Vitreal dihydroxyphenylacetic acid (DOPAC) as an index of retinal dopamine release.
    Megaw P, Morgan I, Boelen M.
    J Neurochem; 2001 Mar; 76(6):1636-44. PubMed ID: 11259481
    [Abstract] [Full Text] [Related]

  • 25. Quantitative MR imaging study of intravitreal sustained release of VEGF in rabbits.
    Alikacem N, Yoshizawa T, Nelson KD, Wilson CA.
    Invest Ophthalmol Vis Sci; 2000 May; 41(6):1561-9. PubMed ID: 10798677
    [Abstract] [Full Text] [Related]

  • 26. Serum, retinal, choroidal vitreal vitamin E concentrations in human infants.
    Bhat R.
    Pediatrics; 1986 Nov; 78(5):866-70. PubMed ID: 3763301
    [Abstract] [Full Text] [Related]

  • 27. Enhanced prostaglandin synthesis after ultraviolet-B exposure modulates DNA synthesis of lens epithelial cells and lowers intraocular pressure in vivo.
    Andley UP, Becker B, Hebert JS, Reddan JR, Morrison AR, Pentland AP.
    Invest Ophthalmol Vis Sci; 1996 Jan; 37(1):142-53. PubMed ID: 8550317
    [Abstract] [Full Text] [Related]

  • 28. [Thermal neodymium:YAG laser effects on the retina].
    Hutter H, Hiemer H, Gabel VP, Birngruber R.
    Fortschr Ophthalmol; 1985 Jan; 82(5):443-6. PubMed ID: 4076965
    [No Abstract] [Full Text] [Related]

  • 29. Ambient illuminance, retinal dopamine release and refractive development in chicks.
    Cohen Y, Peleg E, Belkin M, Polat U, Solomon AS.
    Exp Eye Res; 2012 Oct; 103():33-40. PubMed ID: 22960317
    [Abstract] [Full Text] [Related]

  • 30. Inhibition of vitreoretinal VEGF elevation and blood-retinal barrier breakdown in streptozotocin-induced diabetic rats by brimonidine.
    Kusari J, Zhou SX, Padillo E, Clarke KG, Gil DW.
    Invest Ophthalmol Vis Sci; 2010 Feb; 51(2):1044-51. PubMed ID: 19710406
    [Abstract] [Full Text] [Related]

  • 31. Irradiation of the posterior ocular segment with the neodymium-YAG laser in its free-running mode.
    Fankhauser F, Kwasniewska S, van der Zypen E.
    Arch Ophthalmol; 1985 Sep; 103(9):1406-12. PubMed ID: 3840015
    [Abstract] [Full Text] [Related]

  • 32. Ocular pharmacokinetics of intravitreally administered brimonidine and dexamethasone in animal models with and without blood-retinal barrier breakdown.
    Shen J, Durairaj C, Lin T, Liu Y, Burke J.
    Invest Ophthalmol Vis Sci; 2014 Feb 20; 55(2):1056-66. PubMed ID: 24448267
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. [Retinal damage in neodymium:YAG laser surgery in the area of the vitreous body].
    Hiemer H, Hutter H, Gabel VP, Birngruber R.
    Fortschr Ophthalmol; 1985 Feb 20; 82(5):447-9. PubMed ID: 4076966
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. REDUCTION OF VITREOUS PROSTAGLANDIN E2 LEVELS AFTER TOPICAL ADMINISTRATION OF INDOMETHACIN 0.5%, BROMFENAC 0.09%, AND NEPAFENAC 0.1.
    Russo A, Morescalchi F, Vezzoli S, Bernini M, Turano R, Costagliola C, De Ferrari F, Semeraro F.
    Retina; 2016 Jun 20; 36(6):1227-31. PubMed ID: 26562569
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 5.